Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
Tampa Bay Company Searching for Other Vaccine Methods
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, is in the pre-clinical phase of developing a vaccine they say would solve two critical problems when it comes to ending the pandemic.
Oragenics Chases Vaccine for Niche Markets
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.
Biotech Firm Raises $20 Million, Sees Progress on COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc. has raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine.
SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.
Oragenics CEO Alan Joslyn Recognized As Health Care Innovator 2020 on Tampa Bay Business Journal
The Tampa Bay Business Journal recognized Alan Joslyn, president and chief executive officer of UF startup and UF Innovate | Sid Martin Biotech graduate... Read More
FDA Broadly Supports Oragenics’ Pre-IND Development Program for Its SARS-CoV-2 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., and Avid Bioservices, Inc., announced that they have entered into a process... Read More
Tiny Florida Medical Research Firm Faces Giant Challenge — COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a Tampa-based medical research business with roots in Gainesville, found itself at... Read More
